CA
NZ
UK
AU
IND
US
UnitedHealth Group NYSE:UNH is declining 1.6%, the weakest large-cap healthcare name today, as ongoing DOJ Medicare billing scrutiny, a first revenue decline guidance in a decade, and persistent medical cost uncertainty maintain institutional caution.Key HighlightsUnitedHealth is falling to $402.62, the weakest large-cap healthcare name …
Merck and Co NYSE:MRK is essentially unchanged as Keytruda's oncology pipeline remains on track, providing stability in a session where a competitor's Phase 3 lung cancer trial failure has highlighted broader pharma pipeline risk.Key HighlightsMerck is trading fractionally higher at $119.83, holding near flat …
Pfizer (NYSE:PFE) is declining close to 1% to $24.49 in Wednesday's session, extending a pattern of consistent selling pressure as two overlapping negative developments maintain downward momentum on the stock.
Thermo Fisher Scientific NYSE:TMO is surging more than 3.5%, one of the session's biggest healthcare gainers, as value-oriented buyers step in following a year-to-date decline of more than 20% that has left the stock deeply oversold relative to long-term earnings power.Key HighlightsThermo Fisher is …
The nicotine pouches market is a growing sector, with companies like ALP expanding their reach into new regions. This expansion is driven by increasing demand for tobacco alternatives, with nicotine pouches being a popular choice among consumers. The market is expected to continue growing, …
In intraday trading, Eli Lilly NYSE:LLY edged marginally higher near a multi-week high as sustained demand for Mounjaro and Zepbound in the GLP-1 market supported cautious institutional accumulation ahead of upcoming results.Key HighlightsAs of the latest intraday update, Eli Lilly edged to approximately $1,110, …
Fate Therapeutics Inc (NASDAQ: FATE) is a biotechnology company focused on developing new treatments for various diseases. The company's pipeline includes several promising new therapies, including FT819. Fate Therapeutics Inc (NASDAQ: FATE) is committed to advancing its pipeline and bringing new treatments to market.
In intraday trading, Gilead Sciences NASDAQ:GILD edged marginally higher but remains well below its 52-week high as pipeline catalyst uncertainty and competitive HIV dynamics limit institutional buying interest.Key HighlightsAs of the latest intraday update, Gilead Sciences gained a fraction to $125.34, a significantly smaller …
In intraday trading, Intuitive Surgical NASDAQ:ISRG inched marginally higher but remains near multi-year lows as hospital capital constraints, reimbursement scrutiny, and slower-than-expected da Vinci 5 adoption weigh on the stock.Key HighlightsAs of the latest intraday update, Intuitive Surgical gained a fraction to $404.24, trading …
Johnson & Johnson (NYSE:JNJ) is edging higher to $240.07 in Wednesday's session as investors rotate into large-cap healthcare names amid a broader market rebound, with the S&P 500 advancing approximately 0.74% intraday.
Please wait processing your request...